TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
The user experiences histamine intolerance with alcohol-based hair loss treatments like Rogaine foam and seeks alternatives. Suggestions include alcohol-free and PPG-free topical minoxidil or finasteride, and trying Spectral products with different solvents.
The conversation discusses the potential use of thermal paper receipts, which contain estrogen, as a treatment for hair loss. Participants humorously debate its effectiveness compared to established treatments like Minoxidil and finasteride.
The conversation is about finding a source to buy RU58841 in Germany, specifically looking for a PG-free option. Users suggest buying powder and mixing it themselves, with one user recommending a specific website.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
Applying vitamin E capsules, specifically tocotrienols, on the scalp for hair regrowth. Users are skeptical about its effectiveness due to lack of evidence.
Finasteride may affect prostate sensation and size, with some users reporting easier urination. Concerns exist about prostate shrinkage even at lower doses.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
The post discusses allergens in everyday shampoos and skincare products, listing yearly allergens from 2000 to 2023. It suggests that these chemicals might contribute to acne and hair loss.
Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.
The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.